COMPANY:

Strata Oncology

"Strata Oncology, Inc...today announced that it will present new data in scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) taking place December 1-3, 2023 in Chicago, Illinois and the San Antonio Breast Cancer Symposium (SABCS) taking place December 5-9, 2023 in San Antonio, Texas....The data to be presented includes results for innovative, proprietary predictive biomarkers for response to anti-PD-1/PD-L1 immunotherapy and antibody-drug conjugates (ADCs) -- the Immunotherapy Response Score (IRS) and ADC Treatment Response Score (ADC TRS), respectively."

P=NA | N=200 | "A pre-specified blinded analysis of more than 200 NSCLC patients initially treated with pembrolizumab either alone or in combination with chemotherapy, showed that IRS was significantly associated with time-to-next-treatment (TTNT) independent of therapy type and PD-L1 IHC by tumor proportion score (TPS). Subgroup analysis demonstrated that among patients with PD-L1 High (TPS>=50%), IRS High patients had significantly longer single-agent pembrolizumab TTNT than IRS Low patients, illustrating the opportunity to fill a clear unmet need....'In NSCLC with PD-L1 TPS>=50%, guidelines recommend either pembrolizumab alone or in combination with chemotherapy...."

"Strata Oncology, Inc...today announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer. The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit....The Immunotherapy Response Score integrates relevant biological factors (TMB, PD-L1, PD-1, and tumor microenvironment components) into a simple score to predict immunotherapy benefit across all solid tumors."

"Strata Oncology, Inc....announced that it will present new data in four scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023 in Orlando, Florida. The data to be presented includes results for innovative, proprietary predictive biomarkers for fam-trastuzumab-deruxtecan-nxki, sacituzumab govitecan and pembrolizumab. Strata has developed these biomarkers and others using data collected through an observational clinical trial protocol called the Strata Trial® (NCT03061305). All of these biomarkers take advantage of the company's unique molecular profiling platform that combines DNA and quantitative RNA sequencing on a single small tumor tissue sample."

"Strata Oncology...announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS). The study was published by Communications Medicine, a Nature publication....Key findings from the study include: IRS predicted real-world progression-free survival and overall survival in anti-PD-1/PD-L1 monotherapy treated patients across tumor types....In non-small cell lung cancer (NSCLC) patients who were IRS-high, there was no significant benefit of combination therapy (pembrolizumab + chemotherapy) compared to monotherapy (pembrolizumab)."

"Strata Oncology, Inc...announced the integration of discrete genomic data from its StrataNGS® next-generation sequencing-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module....The integration will streamline workflows for physicians by creating an easily-accessible and user-friendly database, allowing them to more quickly identify the optimal therapy for each patient with cancer. This integration will also enable the institution to expand its research and understanding of cancer."

"Strata Oncology, Inc...announced that Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center have joined as clinical trial sites in the Strata SentinelTM trial, a prospective, observational study of the StrataMRD^TM minimal residual disease test that has the potential to shift the paradigm of cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease."

"Strata Oncology, Inc...announced that...will participate in two panel discussions at the Precision Medicine World Conference (PMWC) 2022, being held live from June 28-30 in Santa Clara, CA...Title: Dismantling Barriers to Biomarker Testing Through Collaboration"

"Strata Oncology, Inc...announced enrollment of the first patient in the Strata Sentinel trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD test to detect cancer recurrence in advance of standard of care techniques across solid tumors, as well as the clinical benefit of treatment in early-stage patients who are or become ctDNA-positive after surgery or other therapy with curative intent."